Ab
|
Antibody
|
AE
|
Adverse event
|
ANCOVA
|
Analysis of covariance
|
ARR
|
Annualised Relapse Rate
|
Avonex
|
IFN β-1a (tradename)
|
BBB
|
Blood-brain barrier
|
BG-12
|
Dimethyl fumarate
|
CD25
|
Interleukin-2 receptor, alpha subunit
|
CER
|
Clinical Evaluation Report
|
CI
|
Confidence interval
|
CNS
|
Central nervous system
|
DAC HYP
|
Daclizumab High Yield Process
|
DAC Penzberg
|
Daclizumab, Penzberg investigational form
|
EDSS
|
Expanded Disability Status Scale
|
EE
|
Efficacy-evaluable (population)
|
EEDS
|
Expanded Disability Status Scale
|
EMA
|
European Medicines Agency
|
Gd
|
Gadolinium
|
IFN
|
Interferon
|
IFN-β
|
Interferon beta
|
IgG
|
Immunoglobulin G
|
IL-2
|
Interleukin-2
|
IL-2Rα
|
Interleukin-2 receptor, alpha subunit
|
IM
|
Intramuscular
|
INEC
|
Independent Neurology Evaluation Committee
|
INEC
|
Independent Neurology Evaluation Committee
|
ISR
|
Injection site reaction
|
ITT
|
Intent-to-treat
|
IVRS
|
Interactive Voice Response System
|
JC
|
John Cunningham
|
LTi
|
Lymphoid tissue inducer (cells)
|
MAb
|
Monoclonal antibody
|
MRI
|
Magnetic Resonance Imaging
|
MS
|
Multiple sclerosis
|
MSFC
|
Multiple Sclerosis Functional Composite
|
MSIS-29
|
Multiple Sclerosis Impact Scale 29
|
NK
|
Natural killer (cells)
|
PD
|
Pharmacodynamic
|
PFS
|
Pre-filled syringe
|
PI
|
Product Information
|
PK
|
Pharmacokinetic
|
PPMS
|
Primary progressive multiple sclerosis
|
PRMS
|
Primary-relapsing multiple sclerosis
|
QoL
|
Quality of life
|
RRMS
|
Relapsing and remitting multiple sclerosis
|
SC
|
Subcutaneous(ly)
|
SCE
|
Summary of Clinical Efficacy
|
SCER
|
Supplementary Clinical Evaluation Report
|
SCS
|
Summary of Clinical Safety
|
SDMT
|
Symbol Digit Modalities Test
|
SOC
|
System organ class
|
SPMS
|
Secondary progressive multiple sclerosis
|
TGA
|
Therapeutic Goods Administration
|
VFT
|
Visual Function Test
|
